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When activated, B cells can differentiate either into
memory B cells, or into plasma cells, which secrete the B
cells antibody at high rates. Plasma cells can be short-
lived or long-lived. Long-lived plasma cells are main-
tained mostly in the bone marrow, in privileged survival
niches, which are organised by dedicated stroma cells [1].
Long-lived plasma cells constitute a discrete type of
immunological memory cells, providing humoral protec-
tion to recurrent pathogens. In immune-mediated dis-
eases, like allergy or inflammatory rheumatic diseases,
however, memory plasma cells can turn detrimental, con-
stantly providing pathogenic antibodies. In systemic
lupus erythematosus (SLE), autoreactive memory plasma
cells, secreting antibodies against self antigens such as
DNA, are readily detectable. These cells represent a ther-
apeutic challenge. While short-lived plasma cells,
respectable their precursors and their generation, are tar-
geted by conventional immunosuppression with drugs
such as cyclophosphamide, memory plasma cells do not
respond, continue to secrete antibodies, and thus sustain
persistence of disease [2,3]. New therapies, targeting
memory plasma cells, have to be developed, to meet this
challenge. Several different therapeutic strategies have
been proposed so far.One of the more promising strate-
gies aims at the inhibition of proteasomes, since this
strategy has been shown to be effective to eliminate mul-
tiple myeloma cells, i.e. transformed plasma cells. In a
f i r s ts t u d y ,N e u b e r ta n dc o l l e g u e sc o u l ds h o wi n2 0 0 8
that in the NZB/W mouse model of SLE, memory plasma
cells are depleted from spleen and bone marrow by the
proteasome inhibitor bortezomib (Velcade) [4]. Clinically,
treated mice showed reduced nephritis and prolonged
survival.
Consequently, the groups of ReinhardVoll and our
group initiated a clinical trial of bortezomib for the treat-
ment of patients with SLE. Those patients had not
responded to other treatments earlier and showed persis-
tent autoantibody titers, indicating the presence of auto-
reactive memory plasma cells. Four patients with active
SLE, previously treated with cyclophosphamide, received
bortezomib (Velcade
®) at doses of 1.3mg/m
2 on days +1,
4, 8, 11 followed by a 10 days treatment-free interval for
four cycles along with 20mg dexamethasone according to
the approved myeloma protocol. Under proteasome inhi-
bition, a significant clinical improvement was achieved in
all patients associated with a reduction in lupus-specific
autoantibodies. In addition, protective, vaccine-specific
antibodies and total immunoglobulin levels dropped sig-
nificantly, suggesting a depletion of bone marrow memory
plasma cells secreting these antibodies.In all patients, like
in the NZB/W mice, repeated treatment was needed for
sustained efficacy, indicating that autoreactive memory
plasma cells are continuously generated in chronic disease.
Thus, a therapeutic regimen combining B cell depletion
with memory plasma cells depletion might be preferable.
First experiments in NZB/W mice showed a sustained
effect of combination therapies depleting plasma cell pre-
cursors as well as fully differentiated plasma cells.
In conclusion proteasome inhibition in SLE has demon-
strated the therapeutic relevance of autoreactive memory
plasma cells as such, and it constitutes a new therapeutic
option, which has to be developed with respect to sus-
tained effectivity, minimization of side effects and reduc-
tion of risk of infection.
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